---
schema_version: "secwatch.filing_event.v1"
accession: "0001847903-25-000154"
form_type: "8-K"
ticker: "CNTA"
cik: "0001847903"
company_name: "Centessa Pharmaceuticals plc"
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:24:23.045673+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Centessa reports Q3 net loss of $54.9M; ORX750 Phase 2a meets endpoints in NT1, NT2, IH

## Summary
- Net loss of $54.9M in Q3 2025 vs $42.6M in Q3 2024; R&D expenses rose to $41.6M.
- Cash and investments $349M as of Sep 30, 2025, expected to fund operations into mid-2027.
- ORX750 Phase 2a showed statistically significant improvements on MWT, ESS, and cataplexy rate across NT1, NT2, and IH at low doses.
- ORX142 Phase 1 demonstrated rapid onset and differentiated PK; patient studies planned for Q1 2026.
- Registrational program for ORX750 expected to start Q1 2026; ORX489 IND-enabling studies ongoing.

## SEC filing metadata
- accession: 0001847903-25-000154
- form_type: 8-K
- ticker: CNTA
- cik: 0001847903
- company_name: Centessa Pharmaceuticals plc
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847903/000184790325000154/0001847903-25-000154-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847903/000184790325000154/cnta-20251105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001847903-25-000154
- JSON: https://secwatch.observer/filing/0001847903-25-000154.json
- Plain text: https://secwatch.observer/filing/0001847903-25-000154.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.